Skip to main content

Dr. David R. Liljenquist, MD

Endocrinology & Diabetes (Endocrinology, Diabetes & Metabolism Physician)

  • Medicare participating

At a glance

Years since graduation
25
In the NPI registry since
2005
Medicare patients seen, 2024
844

The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is

Education and training

  • 2001Medical school: George Washington University School of Medicine
  • 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier

Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).

Specialties and state licenses

  • Endocrinology, Diabetes & Metabolism Physician primary
    ID license M9285

As reported to the NPI registry. To confirm a license is current, check the state medical board.

Map: Endocrinology & Diabetes per capita by county →

Where they work

Hospitals

Medical groups

Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.

Medicare patients and services

Medicare patients, 2024
844
Services billed
15,520
Patients’ average age
73
Most frequent Medicare services, 2023
ServiceTimesPatients
Injection, romosozumab-aqqg, 1 mg14,28011
Insertion of needle into vein for collection of blood sample963682
Injection, denosumab, 1 mg96012
Established patient office or other outpatient visit, 30-39 minutes770593
Hemoglobin a1c level583444
Blood test, thyroid stimulating hormone (tsh)366289
Kidney function blood test panel318280
Blood test, lipids (cholesterol and triglycerides)310287
Parathormone (parathyroid hormone) level279237
Vitamin d-3 level223208

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 24 companies reported 57 payments worth $1,126 in total to this clinician.

By type
Food and Beverage$1,060
Education$65.97

What the payments were for

Largest payments other than meals
DateCompanyWhat it was forAmount
Oct 27, 2025Chiesi USA, Inc.
Oct 27, 2025
Education
MYCAPSSA · ACROMEGALY
$65.97

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in Idaho →

Industry-funded research

Named as a principal investigator on 12 industry-funded studies in 2025, from 6 companies. The companies reported $1,557,391 in research payments for these studies, mostly to the institutions running them.

  • Senseonics CTP0041
    Senseonics, Incorporated
  • Senseonics CTP-0039
    Senseonics, Incorporated
  • Innovative Automated Insulin Delivery System for Type 2 Diabetes
    Sequel Med Tech, LLC · Completed · NCT06853990
  • A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants
    AbbVie Inc. · Active, not recruiting · NCT06345339
  • Multi-session evaluation of the investigational dexcom continuous glucose monitoring (cgm) system in adult participants
    Dexcom, Inc.
  • ISM2309001A--Janus 1
    Abbott Laboratories
  • NCT02073058--Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System
    Abbott Laboratories
  • M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants
    AbbVie Inc.
  • Senseonics CTP0039
    Senseonics, Incorporated
  • A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants
    AbbVie Inc.

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Endocrinology & Diabetes clinicians in Idaho Falls

Sources

NPI registry (CMS NPPES, November 2026; record last updated September 21, 2021), Medicare Care Compare, Medicare Physician & Other Practitioners (2024), Medicare Part D Prescribers (2024) and Open Payments (2025). Information is self-reported or billed data and may be out of date; call before visiting.

NPI 1932109931. Official NPI registry record (opens in a new tab). Clinicians can correct their information in NPPES; changes appear here after our next monthly update.